US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 00:15:54 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
- Free Extracurricular Classes Nurture Talents of Tibetan Children
- Kunming Combines Jacaranda Scenery, Cultural Creativity to Boost Tourism
- Chinese Lawmakers to Mull Tougher Law Against Women Trafficking
- Jon Wysocki dead at 53: Staind drummer passes away
- China Strengthens Legal Aid for Abducted Women
- Art Class Enables Children with Autism to Socialize
- China to Issue Commemorative Coins on Auspicious Culture
- China's first intelligent offshore drilling platform installed